Pigmentation Disorder Treatment - Market Insights, Competitive Landscape, and Market Forecast - 2030

The global pigmentation disorder market is estimated to grow at a CAGR of 7.31% during the forecast period from 2024 to 2030. The pigmentation disorder market is witnessing considerable market growth primarily owing to the increasing prevalence of various pigmentation disorders. Further, the growing expenditure by young adults on dermatological treatments along with the surging awareness among youngsters about aesthetic appearance, and other factors will ultimately support the market of pigmentation disorders. Also, increasing demand for minimally invasive approaches such as dermabrasion, and laser among others will likely contribute towards pushing the market of pigmentation disorder in the forthcoming years. Similarly, the increasing research & developmental activities along with the rising drug and device approvals will create a requisite for pigmentation disorder in the market. Therefore, the market for pigmentation disorder is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

Pigmentation Disorder Market Dynamics:

One of the key factors influencing the growth of the pigmentation disorders market is the increasing prevalence of various pigmentation disorders such as albinism, melasma, vitiligo, solar lentigines, ephelides (freckles), and others, across the globe.

For instance, as per the United Nations report (2023), it was estimated that in North America and Europe 1 in every 17,000 to 20,000 people have some form of albinism.

As per the above-mentioned source, the condition of albinism is much more prevalent in sub-Saharan Africa, with estimates of 1 in 1,400 people being affected in Tanzania and prevalence as high as 1 in 1,000 reported for select populations in Zimbabwe and other specific ethnic groups in Southern Africa.

According to the latest study done by Global Vitiligo Foundation, nearly 70 million people across the world had vitiligo, in 2022.

The pigmentation diseases are treated with various topical medicines, chemical peels, cryotherapy, light or laser therapy, or a combination of these techniques to address the underlying illness. Thus, the increasing prevalence of various pigmentation disorders globally will increase the demand for topical medicines or cosmetic procedures, thereby propelling the overall market growth of pigmentation disorders during the forecast period from 2022 - 2028.

Lastly, the increasing strategic development in the market such as rising product approvals, and launches are further increasing the growth of the pigmentation disorder treatment market. For instance, in July 2022, Incyte Corporation received approval from the United States Food and Drug Administration for Opzelura (ruxolitinib) cream for the treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.

Therefore, the factors stated above collectively will drive the overall pigmentation disorder market throughout the forecast period from 2024-2030.

However, the high cost of cosmetic procedures, lack of skilled professionals, and others may halt the market growth of pigmentation disorders during the forecast period.

The pigmentation disorder market was moderately impacted during the period of COVID-19 pandemic. At the onset of the disease, there was a significant shortage of devices and drugs in the market, attributed to the imposition of stringent lockdowns to curb the spread of the virus. Moreover, treatment for patients suffering from pigmentation disorders was not a priority in comparison to the patients that were suffering from coronavirus, resulting in a lesser number of treatment sessions in the hospital or dermatological clinics. Additionally, owing to the disruption in the supply chain and raw materials, the production of certain treatment products was shut down. However, with the availability of certain pigmentation creams, serums, and other pigmentation treating products over the e-commerce platforms, the market witnessed a moderate rise also. Thus, the above factor was responsible for bringing the market of pigmentation disorder back on track and is anticipated to do the same during the forecast period.

Pigmentation Disorder Market Segment Analysis:

Pigmentation Disorder Market by Treatment (Pharmacological Treatment [Corticosteroids, Calcineurin Inhibitors, and Others] and Non-Pharmacological/Cosmetic Treatment [Chemical Peels, Laser Treatment, Phototherapy, and Others]), Indication (Albinism, Vitiligo, Melasma, Post-Inflammatory Hyperpigmentation (PIH), and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the treatment segment of the pigmentation disorder market, the corticosteroids segment is expected to have a significant revenue share in the year 2023. This is owing to the various advantages and applications that are associated with the segment. Further, various strategic steps taken by the key players pertaining to corticosteroids for pigmentation disorders will aid in driving the market of corticosteroids during the forecast period.

The topical corticosteroids (TC) application showed quick amelioration of post-inflammatory hyperpigmentation patches. Moreover, corticosteroid drugs are used for the treatment of various pigmentation diseases such as albinism, melasma, vitiligo, solar lentigines, ephelides (freckles), and others.

Also, corticosteroids may be used with non-pharmacological treatment for fasting the process of pigmentation treatment.

Further, various developmental activities by key players such as acquisitions, launches, partnerships, and others will also increase the demand for corticosteroids in the market. For instance, in July 2022, Ahammune Biosciences collaborated with Veeda Clinical Research Limited for investigating AB1001 as a topical therapy for vitiligo.

Therefore, owing to the above-mentioned factors, the demand for corticosteroids will increase during the forecast period, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the global pigmentation disorder market.

North America is expected to dominate the overall Pigmentation Disorder Market:

Among all the regions, North America is expected to dominate the global pigmentation disorder in the year 2023 and is expected to do the same during the forecast period from 2024-2030.

This domination is due to the increasing prevalence of pigmentation disorders, the rising geriatric population prone to pigmentation disorders, and technological advancements in treatment options that will boost the pigmentation disorders Market in North America.

For instance, as per the report, people with albinism worldwide, 2022 in the United States, the prevalence of oculocutaneous albinism type 2 was 1 in 6,500 people, in 2022. The increasing prevalence of albinism will increase the demand for topical drugs and cosmetic procedures employed in the treatment of pigmentation disorder.

Further, the availability of various products by the top market competitors, including Obagi Cosmeceuticals, Alvogen, and AbbVie Inc., and increasing business strategies such as mergers, acquisitions, and product launches to strengthen their market position are all anticipated to fuel the market expansion.

For instance, in February 2020, Eli Lilly acquired Dermira for USD 1.1 billion. This acquisition assists the company to expand its pipeline of dermatology medicines, and others with the addition of lebrikizumab, for the treatment of moderate-to-severe atopic dermatitis in adolescent and adult patients, ages 12 years and older and QBREXZA, for the topical treatment of primary axillary hyperhidrosis, respectively.

Therefore, the interplay of the aforementioned factors would provide a conducive growth environment for the pigmentation disorder market in North America.

Pigmentation Disorder Market Key Players:

Some of the key market players operating in the pigmentation disorder market include AbbVie Inc., DERMAMED SOLUTIONS, obagi Cosmeceuticals LLC., Incyte Corporation., Pierre Fabre group, GALDERMA LABORATORIES, L.P., Alvogen., SkinCeuticals., Arcutis Biotherapeutics, Inc., Bausch Health Companies Inc., Dr. Reddy’s Laboratories Ltd, Dermavant Sciences, Inc., Glenmark Pharmaceuticals, Zerigo Health., Novartis AG, Pfizer Inc., Merz GmbH & Co. KGaA, Viatris Inc., Uniza Healthcare, PCA SKIN, and others.

Recent Developmental Activities in the Pigmentation Disorder Market:

• In February 2022, Scientis, an emerging leader in the science of skin discoloration, announces the launch of Cyspera® Intensive System™, a new three-product system clinically proven to improve hyperpigmentation such as persistent brown patches and dark spots.
• In February 2020, PCA SKIN launches two of its most popular chemical peels. These new launches have been added to its extensive lineup of custom blended peel options. The new trichloroacetic (TCA) peel formulas include PCA SKIN Sensi Peel, for people with sensitive skin, PCA SKIN Ultra Peel which can be used for many other skin types, conditions, and sensitivities, and PCA SKIN MD Peel (CCl3) which is most suitable for resilient skin.

Key Takeaways from the Pigmentation Disorder Market Report Study

• Market size analysis for current pigmentation disorder market size (2023), and market forecast for 6 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the pigmentation disorder market.
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global pigmentation disorder market.
• Various opportunities available for the other competitor in the pigmentation disorder market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current pigmentation disorder market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for pigmentation disorder market growth in the coming future?

Target Audience who can be benefited from this Pigmentation Disorder Market Report Study

• Pigmentation disorder providers
• Research organizations and consulting companies
• Pigmentation disorder-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in pigmentation disorder
• Various end users who want to know more about the pigmentation disorder market and the latest developments in the pigmentation disorder market.

Frequently Asked Questions for the Pigmentation Disorder Market:

1. What is pigmentation disorder?

The pigmentation disorders include a large number of diverse conditions that are usually characterized by altered melanocyte density, melanin concentration, or both and result in altered pigmentation of the skin. Pigmentation disorders are classified as hypopigmentation and hyperpigmentation. In hypopigmentation, the pigment is decreased, whereas, in depigmentation, the pigment is completely lost, leaving white skin.

2. What is the global market for pigmentation disorder?

The global pigmentation disorder market is estimated to grow at a CAGR of 7.31% during the forecast period from 2024 to 2030.

3. What are the drivers for the global pigmentation disorder market?

The pigmentation disorder market is witnessing positive market growth owing to the factors such as the increasing prevalence of pigmentation disorders, growing expenditure on dermatological treatments, surging awareness among youngsters about aesthetic appearance, increasing demand for minimally invasive approaches such as dermabrasion, laser, and other, surging new drug launches and approvals, presence of key players in the market, and others will create an exigency for the pigmentation disorder market.

4. Who are the key players operating in the global pigmentation disorder market?

Some of the key market players operating in the pigmentation disorder market include AbbVie Inc., DERMAMED SOLUTIONS, obagi Cosmeceuticals LLC., Incyte Corporation., Pierre Fabre group, GALDERMA LABORATORIES, L.P., Alvogen., SkinCeuticals., Arcutis Biotherapeutics, Inc., Bausch Health Companies Inc., Dr. Reddy’s Laboratories Ltd, Dermavant Sciences, Inc., Glenmark Pharmaceuticals, Zerigo Health., Novartis AG, Pfizer Inc., Merz GmbH & Co. KGaA, Viatris Inc., Uniza Healthcare, PCA SKIN, and others.

5. Which region has the highest share of the pigmentation disorder market?

Among all the regions, North America is estimated to hold a significant revenue share in the global pigmentation disorder market. This can be ascribed to the due the increasing prevalence of pigmentation disorders, the rising geriatric population prone to pigmentation disorders, advancements in devices and drugs, the rising awareness about skincare, and the presence of key domicile players in the region are the reasons which act as a supportive factor for the North America pigmentation disorder market growth.


This product will be delivered within 2 business days.